Lexeo Therapeutics (NASDAQ:LXEO) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Lexeo Therapeutics (NASDAQ:LXEO) issued its quarterly earnings results on Monday. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09, Zacks reports.

Lexeo Therapeutics Price Performance

Shares of LXEO stock opened at $4.44 on Wednesday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.50. The firm has a fifty day moving average of $4.12 and a 200-day moving average of $6.67. The firm has a market capitalization of $146.81 million, a price-to-earnings ratio of -1.41 and a beta of 3.85.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LXEO shares. Royal Bank of Canada reduced their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday. Finally, Leerink Partners cut their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.